Skip to Content

Endari Approval History

  • FDA approved: Yes (First approved July 7th, 2017)
  • Brand name: Endari
  • Generic name: L-glutamine
  • Dosage form: Oral Powder
  • Company: Emmaus Life Sciences Inc.
  • Treatment for: Anemia, Sickle Cell

Endari (L-glutamine) is orally-administered pharmaceutical grade L-glutamine (PGLG), an amino acid formulation to relieve pain, swelling and other complications of sickle cell anemia.

Development History and FDA Approval Process for Endari

DateArticle
Jul  8, 2017Approval FDA Approves Endari (L-glutamine oral powder) for Sickle Cell Disease
May 24, 2017FDA Advisory Committee Recommends Approval of Endari from Emmaus Life Sciences for the Treatment of Sickle Cell Disease
Nov  8, 2016Emmaus’ New Drug Application for Sickle Cell Disease Accepted for Review by FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide